Anti-Obesity Drugs and Female Reproductive Dysfunction: A Mechanistic Review

This narrative review synthesizes mechanistic and clinical evidence on how weight-loss pharmacotherapy, especially incretin-based agents and metformin, may indirectly improve reproductive outcomes in women with obesity and PCOS.

GLP-1 receptor agonistsliraglutidesemaglutideexenatidetirzepatidemetforminorlistatphentermine/topiramatenaltrexone/bupropionobesityPCOSinfertilityfemale reproductive healthnarrative reviewwomen's health Women's Health / Reproductive

Background Information

Anti-obesity drugs show promise for enhancing reproductive health in obese women.

Obesity significantly affects female reproductive health, leading to conditions like polycystic ovary syndrome (PCOS) and infertility. GLP-1 receptor agonists like liraglutide and semaglutide show promise in improving reproductive outcomes by enhancing insulin sensitivity and ovulation. While some anti-obesity drugs offer reproductive benefits, concerns remain over safety in pregnancy, highlighting the need for more research. Anti-obesity drugs, especially GLP-1 agonists, may improve reproductive health in obese women but require caution and further study.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Varra FN, Theodosis-Nobelos P, Varra VK, Varras M

Citation: Varra FN, Theodosis-Nobelos P, Varra VK, et al. Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies. Medicina (Kaunas, Lithuania). 2026;62(8). doi:10.3390/medicina62081445

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →